A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates

This is an exploratory study designed to evaluate the efficacy of eribulin in combination with anlotinib in patients with HER2-negative recurrent or metastatic breast cancer who have experienced treatment failure with antibody-drug conjugates (ADCs). The study aims to assess the efficacy and safety of eribulin combined with anlotinib in the treatment of patients with recurrent or metastatic HER2-low breast cancer, and to provide clinical evidence supporting this novel combination regimen.